The state of Vermont will receive $1.5 million dollars as part of a $62 million settlement with the drug maker Eli Lilly & Co.
The settlement with 32 states and Washington, D.C., resolves an investigation into the company’s marketing practices of Zyprexa, an anti-psychotic medication.
States accused Lilly of marketing Zyprexa for off-label uses, and inadequately disclosing the drug’s side effects to health care providers.
Vermont Attorney General William Sorrell says Eli Lilly’s marketing activities harmed some of the most vulnerable Vermonters, including the elderly and people suffering from mental illness.
The company isn’t acknowledging any wrongdoing.